Predilife

Predilife Gross Margin

The Gross Margin of Predilife (ALPRE.PA) as of Oct 9, 2026 is 98.86 %. In the previous year, Gross Margin was 97.76 % — a change of 1.12% (higher).

Gross Margin

98.86 %

YoY

1.12%

Last updated:

Gross Margin of Predilife is 2025 98.86 % . Gross Margin of Predilife was 2024 97.76 % . It decreases by 1.12% higher compared to the previous year.

Predilife's gross margin stands at 98.9%, up from -1,376.8% several years earlier.

The Predilife Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
87.66 EUR
Jan 1, 2019
-4,977.54 EUR
Jan 1, 2020
-3,088.84 EUR
Jan 1, 2021
-1,376.76 EUR
Jan 1, 2022
84.67 EUR
Jan 1, 2023
95.39 EUR
Jan 1, 2024
97.76 EUR
Jan 1, 2025
98.86 EUR
The Predilife Gross Margin history
YEARGross MarginYoY
98.86 %+1.12%
97.76 %+2.49%
95.39 %+12.66%
84.67 %-106.15%
-1,376.76 %-55.43%
-3,088.84 %-37.94%
-4,977.54 %-5,778.53%
87.66 %+33.07%
65.87 %-100.04%
-170,375.00 %—
Access this data via the Eulerpool API

Predilife Stock analysis

What does Predilife do? Predilife SA is a company specializing in predictive medicine. It was founded in Switzerland in 2011 and has since been based in Marseille, France. The company currently has around 50 employees, most of whom are scientists and doctors. The idea for Predilife SA came from the realization that many diseases can be prevented if they are detected and treated in advance. As most diseases also have a genetic component, Predilife SA focuses on the development of tests that calculate individual disease risk based on individual genetics. The business model of Predilife SA is based on the development and sale of predictive genetic tests for various diseases. The company works with health insurance companies, insurance companies, companies, as well as directly with end customers. The company believes that predictive tests represent an opportunity for many people to detect diseases early and take appropriate preventive measures. The company offers predictive tests for a range of diseases, including cancer, cardiovascular diseases, neurodegenerative diseases, and diabetes. The tests are based on state-of-the-art molecular diagnostic methods that allow for the identification of genetic changes that increase individual disease risk. The tests are conducted in specialized laboratories and interpreted by qualified doctors and geneticists. Predilife SA operates four different divisions and offers a range of predictive tests for each division: Division 1: Cancer prevention This division focuses on tests for common types of cancer such as breast, colon, and prostate cancer. The tests assess the individual risk of developing cancer and help optimize prevention and surveillance measures. Division 2: Cardiovascular diseases This division offers tests that assess the individual risk of cardiovascular diseases such as heart attack or stroke. The results are used to take targeted preventive measures. Division 3: Neurological diseases This division develops tests for neurodegenerative diseases such as Alzheimer's or Parkinson's. The results help determine individual risk and take appropriate preventive measures. Division 4: Diabetes This division offers tests that assess the individual risk of type 2 diabetes. The results are used to take targeted preventive measures. In addition to predictive tests, Predilife SA operates its own research department that focuses on the development of new predictive tests and the further development of existing tests. The company collaborates with leading scientists and institutions worldwide. Overall, Predilife SA aims to make predictive medicine accessible to as many people as possible. The company relies on state-of-the-art technologies and high professional competence. Predilife is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Predilife stock

Gross Margin of Predilife is 98.86 % in 2025.

Gross Margin of Predilife changed from 97.76 % to 98.86 %, representing a 1.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Predilife since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Predilife with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

Margins — Predilife

All Key Metrics — Predilife